To confirm the relationship between PARP1 and CDK4/6i resistance over a wider range, we obtained the IC50 for the CDK4/6i palbociclib in 30 breast cancer cell lines from the GDSC database and paired them with corresponding PARP1 mRNA level data gained from CCLE. Here, CDK4 is linked to breast carcinoma.